{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:34:17Z","timestamp":1794278057337,"version":"4.9.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Black individuals frequently present with resistant hypertension and disproportionately increased cardiovascular risk. We investigated the blood pressure (BP)-lowering effect of the dual endothelin receptor antagonist aprocitentan in Black individuals enrolled in the PRECISION study (Parallel-Group, Phase 3 Study with Aprocitentan in Subjects with Resistant Hypertension).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>Patients with confirmed resistant hypertension were randomized to aprocitentan 12.5 mg, 25 mg, or placebo for 4 weeks (part 1). They subsequently received aprocitentan 25 mg for 32 weeks (part 2) before re-randomization to aprocitentan 25 mg or placebo (part 3).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>Eighty-two patients randomized in the PRECISION study were Black individuals. At week 4, aprocitentan 12.5 and 25 mg reduced office trough systolic BP (\u221211.3 and \u221211.9 mm\u2005Hg) to a similar degree as placebo (\u221212.0 mm\u2005Hg). Using 24-hour ambulatory BP monitoring, the placebo effect was minimal (\u22120.7 mm\u2005Hg), and aprocitentan reduced systolic BP by 4.0 and 8.6 mm\u2005Hg. During part 2, office BP continued to decrease (\u221216.4 mm\u2005Hg at week 36). In part 3, office and ambulatory systolic BP increased on placebo (+9.9 and +8.1 mm\u2005Hg, respectively), whereas the BP-lowering effect was maintained with aprocitentan. Aprocitentan markedly reduced albuminuria during the study. The most frequent adverse event was peripheral edema, occurring in 3 patients (10%) receiving aprocitentan 25 mg versus none receiving aprocitentan 12.5 mg or placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Aprocitentan reduced BP and albuminuria in Black individuals with resistant hypertension. The BP-lowering efficacy was similar to that of the overall PRECISION population. Aprocitentan may represent an important addition to the often difficult-to-control hypertension in Black individuals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>REGISTRATION:<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              ; Unique identifier: NCT03541174.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/hypertensionaha.124.24142","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T10:00:24Z","timestamp":1737540024000},"page":"601-610","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Aprocitentan for Blood Pressure Reduction in Black Patients"],"prefix":"10.1161","volume":"82","clinical-trial-number":[{"clinical-trial-number":"nct03541174","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-5598","authenticated-orcid":true,"given":"John M.","family":"Flack","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Hypertension Section, Departments of Medicine and Population Science and Policy, Hypertension Section, Southern Illinois University School of Medicine, Springfield, IL (J.M.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-0195","authenticated-orcid":true,"given":"Markus P.","family":"Schlaich","sequence":"additional","affiliation":[{"name":"Dobney Hypertension Centre, Medical School - Royal Perth Hospital Unit, University of Western Australia, Australia (M.P.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-0831","authenticated-orcid":true,"given":"Michael A.","family":"Weber","sequence":"additional","affiliation":[{"name":"Downstate College of Medicine, State University of New York, Brooklyn, NY (M.A.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Sassi-Sayadi","sequence":"additional","affiliation":[{"name":"Biometry, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland (M.S.-S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Narkiewicz","sequence":"additional","affiliation":[{"name":"Department of Hypertension and Diabetology, Medical University of Gda\u0144sk, Gda\u0144sk, Poland (K.N.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Clozel","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland (M.C., R.F.D., P.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland F.","family":"Dreier","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland (M.C., R.F.D., P.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil S.","family":"Andrawis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Manassas Clinical Research Center, VA (N.S.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Danaietash","sequence":"additional","affiliation":[{"name":"Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland (M.C., R.F.D., P.D.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa","family":"Gabra","sequence":"additional","affiliation":[{"name":"Burke Internal Medicine and Research, VA (N.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Scott","sequence":"additional","affiliation":[{"name":"Scott Research, Laurelton, NY (D.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8511-1524","authenticated-orcid":true,"given":"Ji-Guang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, The Shanghai Institute of Hypertension, RuiJin Hospital, Shanghai Jiao Tong University School of Medicine, China (J.-G.W.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3338-4410","authenticated-orcid":true,"given":"Keith C.","family":"Ferdinand","sequence":"additional","affiliation":[{"name":"John W. Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA (K.C.F.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","first-page":"1","article-title":"Hypertension prevalence among adults aged 18 and over: United States, 2017\u20132018.","volume":"364","author":"Ostchega Y","year":"2020","unstructured":"Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017\u20132018. NCHS Data Brief. 2020;364:1\u20138.","journal-title":"NCHS Data Brief"},{"key":"e_1_3_3_3_2","first-page":"S19","article-title":"Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes.","volume":"17","author":"Flack JM","year":"1999","unstructured":"Flack JM, Hamaty M. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. J Hypertens Suppl. 1999;17:S19\u2013S24.","journal-title":"J Hypertens Suppl"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12511"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.068064"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.142"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16181"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15064"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000001040"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.117366"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2022-0010"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000023160.67766.f0"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.28.4.652"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.60.3.697"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.1.2.136"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S199051"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200222666210204202815"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.253864"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14504"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02034-7"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14517"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02148"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-023-01282-0"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-014-1662-4"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.15-276584"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001374"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00463-8"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00190.2006"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-6363(99)00110-8"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00344.2003"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.10.4279"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-6363(02)00658-2"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13920"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.3109\/10641969609097908"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.33.5.1169"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-7061(94)00250-F"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1681.1999.03178.x"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13474"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00733-X"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200108000-00017"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)10656-3"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.36.2.282"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0008-6363(01)00558-2"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142976"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.15"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2009060593"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.156976"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30772-X"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000436"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.234930"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2043"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.99.9.1242"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199601000-00023"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.124.24142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T18:03:18Z","timestamp":1742407398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.124.24142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.124.24142"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.124.24142","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}